Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick

Executive Summary

Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.

Advertisement

Related Content

VC Roundup: 2016 US Investment Ends On A Down Note, But Biopharma Has Second-Best Year
Ascletis Eyes Launch Of China’s First Oral HCV Drug, Possible IPO
Deal Watch: J.P. Morgan Brings Continued Brisk Pace Of Transactions
VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
GSK Spin-Out NeRRe Raises £23m For NK Antagonists
Keeping Track: Approvals For Pfizer's Eucrisa, Vericel's Maci; Submissions From Flexion, AcelRx, Ironshore
PIPELINE WATCH: Three Approvals, Three Filings And Two Launches
China’s First Home Grown Novel HIV Drug Shoots For Prime Time
Vaccibody CEO Bonde: Make Undefeatable Diseases Defeatable
Biotech VC dips in 3Q, but 2014 on track to beat 2013

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel